parthenolide has been researched along with sulindac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Marshall, MS; Nakshatri, H; Schmidt, CM; Sweeney, CJ; Wiebke, EA; Yip-Schneider, MT | 1 |
| Crooks, PA; Nakshatri, H; Neelakantan, S; Noble, S; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yiannoutsos, C; Yip-Schneider, MT | 1 |
3 other study(ies) available for parthenolide and sulindac
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Sesquiterpenes; Sulindac; Transcription, Genetic; Transfection | 2005 |
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin D1; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Sesquiterpenes; Sulindac | 2007 |